Keyphrases
Graft-versus-host Disease (GvHD)
100%
Gastrointestinal Involvement
50%
Host Disease
50%
Minnesota
50%
Standard Risk
50%
Steroid-refractory Acute Graft-versus-host Disease
50%
Ruxolitinib
50%
High Risk
35%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
25%
Emerging Therapies
25%
Response Rate
25%
Survival Benefit
25%
Overcoming Resistance
25%
Treatment Landscape
25%
Pathophysiology
25%
Steroid-refractory
25%
GVHD Prophylaxis
25%
Successful Outcome
25%
Refractory Cases
25%
Lower Gastrointestinal Tract
21%
Clinical High Risk
14%
Upper Gastrointestinal Tract
14%
Micro-capacity
12%
Non-relapse Mortality
7%
Clinical Trial Design
7%
Consecutive Patients
7%
High-risk Population
7%
Clinical Trials
7%
Retrospective Analysis
7%
Newly Diagnosed Patients
7%
Favorable Outcome
7%
Single Center
7%
Instrument Validation
7%
Disease Risk Prediction
7%
Systemic Corticosteroids
7%
Risk Stratification
7%
Multivariate Analysis
7%
Immunology and Microbiology
Acute Graft Versus Host Disease
100%
Mesenchymal Stem Cell
50%
Host
50%
Graft-Versus-Host Disease
50%
Cell Transplantation
25%
Hematopoietic Cell
25%
Survival Rate
25%
High Risk Population
7%
Medicine and Dentistry
Host
50%
Acute Graft Versus Host Disease
50%
Mesenchymal Stem Cell
50%
Hematology
50%
Therapeutic Use
12%
Blood Disorder
12%
Cell Therapy
12%
Microenvironment
12%
Corticosteroid
7%
Clinical Trial
7%
Risk Stratification
7%
Multivariate Analysis
7%
High Risk Population
7%
Clinical Trial Design
7%
Non-Relapse Mortality
7%